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the choice and consumption of brand name and generic OHAs
for each outpatient visit in the Deﬁned Daily Dose. RESULTS:
The regression results suggested a positive relationship between
the reimbursement price and probability of prescribing brand
name OHAs (odd ratio : 1.37, 95%CI : 1.36–1.37). The lower
reimbursement price likely results in the lower consumption of
both brand name (1.23; p < 0.01) and generic (0.93; p < 0.01)
OHAs. The price elasticity of brand name OHAs is greater than
that of generics OHAs. Large scale and private hospitals tend to
prescribe generic OHAs, and those with higher accreditation
level are inclined to prescribe brand name OHAs. CONCLU-
SION: The NHI price regulation generates the proﬁt margin
between reimbursement price and acquisition cost. Reducing the
reimbursement price may squeeze the proﬁt margin from brand
name drugs, likely resulting in decreasing the probability of pre-
scribing brand name drugs. The consumption of brand name
drugs tends to be more sensitive to price adjustment than that of
generic counterparts.
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OBJECTIVES: This study aims to investigate the relative risk
reduction (RRR) and number-needed-to-treat (NNT) estimates
related to lower limb amputation events among patients with
diabetic foot ulcer wounds using Negative Pressure Wound
Therapy (V.A.C.® Therapy) compared to a similar patient pop-
ulation receiving other wound care treatments. METHODS:
RRR and NNT estimates with NPWT in relation to an ampu-
tation event were evaluated using three distinct data sources.
Two retrospective administrative databases of diabetic ulcer
patients, including a commercial and a Medicare (CMS) popu-
lation, as well as RCT data for diabetic foot wound patients were
evaluated. RRR and NNT for lower limb amputation events
were calculated and compared between groups in each of the
three populations. RESULTS: The commercial data yielded over
3500 patients, the Medicare data included over 12,700 patients,
and the RCT included 162 patients. The RRR in amputation
occurrence with NPWT vs. the control group was 34% for the
commercial patient group and 35% for the Medicare patient
group. The RRR was found to be even greater in the RCT group
where NPWT was associated with over a 70% reduction in the
risk of an amputation event. The NNT to prevent one amputa-
tion event with NPWT therapy was 14 for the commercial
patient group, 18 for the Medicare patient group and 13 for the
RCT group. Target NNTs in the range of 12–35 have been
reported for preventing a subsequent adverse event. CONCLU-
SIONS: Using three different sources, this study is the ﬁrst to
evaluate the effectiveness of NPWT therapy by reporting calcu-
lated RRR and NNT related to lower limb amputations. The
NNT to prevent an amputation event with NPWT therapy was
consistent and low, ranging from 13 to 18. This data suggests
that NPWT therapy is an effective intervention in reducing risk
of amputation events in diabetic ulcer patients.
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OBJECTIVES: Achieving therapeutic goals in Type 2 diabetes
often becomes more difﬁcult as the disease progresses; many
patients eventually require treatment beyond oral hypoglycaemic
agents (OHA). The objective of this meta-analysis was to inves-
tigate which injectable therapies were either superior/inferior to
bedtime-administered insulin glargine, (glargine) for key clinical
outcomes. METHODS: A systematic review of all published
glargine clinical trials (prior to October 2005) was conducted.
Based on pre-deﬁned inclusion criteria, the review encompassed
all randomised controlled trials of at least eight-weeks duration
that compared combination therapies (injectable therapy and
OHA(s)), in insulin naïve patients. A random effects model was
employed to incorporate the variability in between-study condi-
tions. RESULTS: Seven trials met the speciﬁed criteria, with
glargine chosen as the reference regimen. Although biphasic
insulin aspart (BIA) and insulin lispro 75/25 were more efﬁca-
cious than glargine at reducing HbA1c (in unadjusted (adjusted)
analyses further reductions of −0.46 % (−0.41) and −0.39 % (−
0.40) respectively were observed), this increase in efﬁcacy was
also associated with relative increases in the risk of experiencing
hypoglycaemic events for both insulins and increased weight gain
for BIA. Compared to glargine, exenatide and NPH were equally
as efﬁcacious at reducing HbA1c, although patients taking exe-
natide also beneﬁted from weight reduction and a reduced risk
of experiencing a nocturnal hypoglycaemic event. With respect
to fasting blood glucose, exenatide, insulin lispro 75/25 and
NPH were less efﬁcacious than glargine. CONCLUSIONS: This
meta-analysis found a slight increase in efﬁcacy observed with
the two twice-daily insulin regimens compared to glargine;
however this result must be carefully balanced against the
observed increase in adverse events, especially for patients where
weight gain or hypoglycaemic events may be an issue. When
glargine was compared to exenatide, similar HbA1c reduction
was found but exenatide treated patients had fewer nocturnal
hypoglycaemic events and experienced weight loss.
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OBJECTIVE: To determine the time that patients with type 1
and type 2 diabetes remain on their existing therapy whilst
uncontrolled, before starting insulin or intensifying their insulin
regimen. METHODS: A retrospective cohort study was con-
ducted among subjects with type 1 and type 2 diabetes. A total
of 154 clinical practices with continuous data over a 10-year
period from 1st May 1995 until 30th April 2005 were included
in this analysis. The study identiﬁed 9979 individuals with type
1 diabetes (T1) and 62,533 individuals with type 2 diabetes (T2).
Four patient groups were analysed: T1 on premix regimens; T2
prescribed ≥2 orals; T2 on basal regimen and T2 on premix reg-
imens. The main study outcome was the median time to insulin
